RS51819B - Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu - Google Patents

Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu

Info

Publication number
RS51819B
RS51819B YU20050273A YUP27305A RS51819B RS 51819 B RS51819 B RS 51819B YU 20050273 A YU20050273 A YU 20050273A YU P27305 A YUP27305 A YU P27305A RS 51819 B RS51819 B RS 51819B
Authority
RS
Serbia
Prior art keywords
active substance
pharmaceutical preparation
stabilized pharmaceutical
amorphous active
amorphous
Prior art date
Application number
YU20050273A
Other languages
English (en)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Pharmaceuticals D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51819(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.
Publication of RS20050273A publication Critical patent/RS20050273A/sr
Publication of RS51819B publication Critical patent/RS51819B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmaceutski preparat koji sadrži farmaceutsku formulaciju sa amorfnim atorvastatin kalcijumom koji je izložen atmosferi inertnog gasa.Prijava sadrži još 24 patentna zahteva.
YU20050273A 2002-10-11 2003-10-10 Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu RS51819B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino

Publications (2)

Publication Number Publication Date
RS20050273A RS20050273A (en) 2007-06-04
RS51819B true RS51819B (sr) 2011-12-31

Family

ID=32091984

Family Applications (1)

Application Number Title Priority Date Filing Date
YU20050273A RS51819B (sr) 2002-10-11 2003-10-10 Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu

Country Status (21)

Country Link
US (2) US20040077708A1 (sr)
EP (1) EP1608362B1 (sr)
CN (1) CN100372529C (sr)
AR (1) AR041588A1 (sr)
AT (2) ATE354362T1 (sr)
AU (1) AU2003280361B2 (sr)
CY (1) CY1106608T1 (sr)
CZ (1) CZ17610U1 (sr)
DE (2) DE60312049T2 (sr)
DK (2) DK1608362T3 (sr)
ES (1) ES2285205T3 (sr)
FI (1) FI7617U1 (sr)
ME (1) ME00514B (sr)
PT (1) PT1608362E (sr)
RS (1) RS51819B (sr)
RU (1) RU2358727C2 (sr)
SI (2) SI21302A (sr)
SK (1) SK5233Y1 (sr)
TW (1) TWI320709B (sr)
UA (1) UA85544C2 (sr)
WO (1) WO2004032920A1 (sr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US8777011B2 (en) 2001-12-21 2014-07-15 Novartis Ag Capsule package with moisture barrier
EP1653930B1 (en) * 2003-08-05 2007-12-19 Zentiva, a.s. Methods for the stabilization of atorvastatin
EP1577297A1 (en) * 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
JP2008514722A (ja) * 2004-09-30 2008-05-08 ドクター レディズ ラボラトリーズ リミテッド 非結晶性アトルバスタチンカルシウム
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
KR20120128599A (ko) 2009-12-25 2012-11-27 사와이세이야쿠 가부시키가이샤 아트로바스타틴 함유 피복 제제
EP2779999A2 (en) 2011-11-15 2014-09-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
CN107530311A (zh) * 2015-02-03 2018-01-02 卡德门制药有限公司 稳定的曲恩汀制剂
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (sr) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69506122D1 (de) * 1994-09-30 1998-12-24 Becton Dickinson Co Verfahren zur herstellung und verpackung von iontophoretischen pflastern und denselben, um die stabilität und die lagerstabilität zu verbessern
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
ATE418979T2 (de) * 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Also Published As

Publication number Publication date
DK200700025U1 (da) 2007-06-08
FIU20070036U0 (fi) 2007-01-26
PT1608362E (pt) 2007-05-31
US20090012150A1 (en) 2009-01-08
DE20321455U1 (de) 2007-05-24
DE60312049T2 (de) 2007-10-04
EP1608362B1 (en) 2007-02-21
DK1608362T3 (da) 2007-05-14
WO2004032920A1 (en) 2004-04-22
AU2003280361B2 (en) 2009-02-26
ME00514B (me) 2011-10-10
SK50062007U1 (en) 2009-03-05
FI7617U1 (fi) 2007-09-28
CN100372529C (zh) 2008-03-05
CZ17610U1 (cs) 2007-06-18
AR041588A1 (es) 2005-05-26
SI1608362T1 (sl) 2007-12-31
EP1608362A1 (en) 2005-12-28
UA85544C2 (ru) 2009-02-10
SI21302A (sl) 2004-04-30
DE60312049D1 (de) 2007-04-05
AU2003280361A1 (en) 2004-05-04
AT10424U1 (de) 2009-03-15
RS20050273A (en) 2007-06-04
RU2005114485A (ru) 2006-01-27
SK5233Y1 (en) 2009-09-07
TW200501947A (en) 2005-01-16
CY1106608T1 (el) 2012-01-25
US20040077708A1 (en) 2004-04-22
TWI320709B (en) 2010-02-21
DK200700025U4 (da) 2008-03-14
CN1703215A (zh) 2005-11-30
RU2358727C2 (ru) 2009-06-20
ATE354362T1 (de) 2007-03-15
ES2285205T3 (es) 2007-11-16

Similar Documents

Publication Publication Date Title
RS51819B (sr) Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu
ECSP024323A (es) Compuestos organicos
HRP20080564T3 (en) Dihydrotetrabenazines and pharmaceutical compositions containing them
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
RS52169B (sr) Stabilni preparati lakvinimoda
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20073629L (no) Terapeutiske formuleringer av keratinocyttvekstfaktor
ATE403425T1 (de) Feste formulierungen enthaltend eine indolinon verbindung
BRPI0413277A (pt) composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
DE60335991D1 (de) Filmueberzug fuer tabletten und kapletten
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
FI20077133A (fi) Essitalopraamin kiteinen emäs ja essitalopraamiemästä sisältäviä, suussa hajoavia tabletteja
ME00483B (me) Parenteralni sastav paracetamola
RS51115B (sr) Oralne formulacije kladribina
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
NO20054417L (no) Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
NO20083518L (no) Farmasoytisk sammensetning inneholdende amorf atorvastatin
ATE461694T1 (de) Pharmazeutische indapamid-zusammensetzung mit verzögerter freisetzung
ATE464043T1 (de) Pharmazeutische zusammensetzung enthaltend l- arginin
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
EP1852119A4 (en) PHARMACEUTICAL PREPARATION CONTAINING PHENOXAZINIUM DERIVATIVE AS ACTIVE INGREDIENT
BRPI0508805A (pt) composições bioadesivas bifuncionais para implantologia oral
WO2006123358A3 (en) Stabilized atorvastatin-containing formulation
AU2003244257A1 (en) Injectable composition comprising florfenicol as an active ingredient
ATE330623T1 (de) Stabile pharmazeutische zusammensetzung mit erythropoietin